Status:
NOT_YET_RECRUITING
Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care
Lead Sponsor:
Nova Scotia Health Authority
Conditions:
Diabetic Kidney Disease
Type 2 Diabetes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Type 2 diabetes is the leading cause of chronic kidney disease, which can result in serious complications such as kidney failure and heart disease. Although effective medications exist to slow the pro...
Detailed Description
Importance: Diabetes is the leading cause of kidney disease. However, the use of guideline directed medical treatments (GDMT) to slow kidney disease progression and reduce the risk of heart disease re...
Eligibility Criteria
Inclusion
- Adults ≥18 years with T2D and DKD (eGFR≥ 30-60 ml/min/1.73m2 and/or UACR≥3 mg/mmol)
- Adults who do not have primary care provider,
- Adults who are eligible for initiation of treatment with RASi, SGLT2i or nsMRA
Exclusion
- Hypotension
- Type 1 diabetes
- History of allergy or intolerance to either, renin angiotensin system inhibitor (RASi), SGLT2 inhibitor (SGLT2i) and nonsteroidal mineralocorticoid receptor antagonist (nsMRA).
- Already receiving all three medications: RASi, SGLT2i, and nsMRA .
- Exceed algorithm thresholds for potassium levels or eGFR less than 30 mL/min/1.73m²
- Limited life expectancy of less than 1 year
- Followed by a subspecialty physician (e.g., nephrologist or endocrinologist)
- Unable to give consent
Key Trial Info
Start Date :
January 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2028
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT07169422
Start Date
January 1 2026
End Date
July 1 2028
Last Update
September 11 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.